Terbinafine Hydrochloride
Product Images NDC 63629-2807

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terbinafine Hydrochloride (NDC 63629-2807). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3a183255-figure-01 (3a183255 Figure 01)

This is a report of adverse events and discontinuation rates for a drug called Lamisit compared to Placebo. The table lists the occurrences of different symptoms such as headache, gastrointestinal issues (diarrhea, dyspepsia, abdominal pain, nausea, and flatulence), dermatological symptoms (rash, pruritus, and urticaria), and liver enzyme abnormalities. The rates or occurrences are given as percentages for each type of symptom for both Lamisit and Placebo groups. The text mentions that liver enzyme abnormalities were found to be 22 times higher than the upper limit of normal range.*

FDA Label Image

3a183255-figure-02 (3a183255 Figure 02)

FDA Label Image

3a183255-figure-03 (3a183255 Figure 03)

This is a list of common symptoms that could indicate an illness in someone. These symptoms include nausea, stomach (abdominal) pain, rash, headache, vomiting, dizziness, and frequent urination. It is important to seek medical attention if any of these symptoms persist or worsen.*

FDA Label Image

3a183255-figure-04 (3a183255 Figure 04)

This text describes some symptoms and signs that may indicate a liver problem. These include nausea, poor appetite, tiredness, vomiting, upper right abdominal pain, yellowing of the skin or eyes (jaundice), dark urine, and pale or light-colored stools. Patients experiencing these symptoms should seek medical attention for a proper diagnosis and treatment.*

FDA Label Image

Label Image (Lbl636292807)

This is a description of a medication called Terbinafine G that comes in a 250mg tablet form. It is packaged by Bryant Ranch Burbank and manufactured by Cipla LTD. The recommended storage temperature is between 20-25 degrees Celsius (68-77 degrees Fahrenheit) and it should be kept out of reach of children. There is a lot number (#30) and an expiration date (MM/YY) provided. The medication has an NDC code of 6362928071 and 028071107435.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.